You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 8, August 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Response of Parotid Hemangiomas to the Use of Systemic Interferon Alfa-2a or Corticosteroids

Francine Blei, MD; Michael Isakoff, MS; Giovanni Deb, MD

Arch Otolaryngol Head Neck Surg. 1997;123(8):841-844.


Abstract

Objective
To evaluate medical treatment for hemangiomas involving the parotid area with or without other areas of involvement.

Design
Retrospective analysis of pediatric patients treated medically for proliferative hemangiomas of the parotid region with or without hemangiomas in other regions. Indications for treatment included respiratory symptoms relating to hemangiomas of the upper airway, difficulty feeding, rapid rate of growth of the hemangioma, and deformity or obstruction of the ear canal.

Setting
New York University Multidisciplinary Vascular Anomaly Conference, New York, NY, and the Pediatric Oncology Department of Ospedale Pediatrico Bambino Gesu, Rome, Italy.

Patients
Thirteen patients with proliferative hemangiomas in the parotid area were treated medically to inhibit growth and enhance involution of the hemangioma.

Intervention
Six patients were treated with corticosteroids alone (2-4 mg/kg daily). Two patients were treated with corticosteroids (2-4 mg/kg daily) followed by interferon alfa-2a (3 million U/m2 daily) because of a failure to respond to corticosteroid therapy. One patient was treated with interferon alfa-2a alone (3 million U/m2 daily). Four patients were initially treated with interferon alfa2a, then treated with corticosteroids. One of these patients required intralesional corticosteroid therapy for a massively enlarged lip and is therefore included in this group. The other patient was given oral corticosteroids for unknown reasons at another institution. In the remaining 2 patients, there was no response to the use of interferon alfa-2a.

main outcome measures
The size, bulk, and symptoms relating to the hemangiomas of the patients were assessed.

Results
None of the patients had a significant improvement of the lesions of the parotid hemangiomas. In contrast, for those patients with clinical symptoms due to hemangiomas elsewhere or with cutaneous involvement typical of hemangiomas, the symptoms improved with either of the above therapies, and the cutaneous areas demonstrated signs of involution.

Conclusions
The results in the 13 patients in this article demonstrate that hemangiomas in certain anatomic sites, such as the parotid area, may be more resistant to therapy with corticosteroids or interferon alfa-2a. Differences in drug metabolism, caliber of blood vessels, and/or blood flow in the parotid gland may account for this observation.

Arch Otolaryngol Head Neck Surg. 1997;123:841-844



Author Affiliations

From the Division of Hematology and Oncology, the Department of Pediatrics (Dr Blei and Mr Isakoff), and the Institute of Reconstructive Plastic Surgery (Mr Isakoff), New York University Medical Center, New York, NY, and the Division of Hematology/Oncology, Ospedale Pediatrico Bambino Gesu, Rome, Italy (Dr Deb).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Infantile Hemangiomas With Unusually Prolonged Growth Phase: A Case Series
Brandling-Bennett et al.
Arch Dermatol 2008;144:1632-1637.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Parotid Hemangiomas
Yan
AAP Grand Rounds 2004;12:21-21.
FULL TEXT  

Hemangiomas of Infancy: Clinical Characteristics, Morphologic Subtypes, and Their Relationship to Race, Ethnicity, and Sex
Chiller et al.
Arch Dermatol 2002;138:1567-1576.
ABSTRACT | FULL TEXT  

Pathology Quiz Case 2
Yilmaz et al.
Arch Otolaryngol Head Neck Surg 2001;127:1391-1393.
FULL TEXT  

Oral Corticosteroid Use Is Effective for Cutaneous Hemangiomas: An Evidence-Based Evaluation
Bennett et al.
Arch Dermatol 2001;137:1208-1213.
ABSTRACT | FULL TEXT  

An Update on the Treatment of Hemangiomas in Children With Interferon Alfa-2a
Greinwald et al.
Arch Otolaryngol Head Neck Surg 1999;125:21-27.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.